Results for tag: "Chronic Myeloid Leukemia Drug"

Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow. Treatment for CML typically involves the use of drugs that target the abnormal cells that cause the disease. The CML drug market consists of a variety of drugs, including tyrosine kinase inhibitors (TKIs), interferon-alpha, and hydroxyurea. TKIs are the most commonly used drugs for CML, as they are effective in controlling the disease and have fewer side effects than other treatments. Interferon-alpha is used to reduce the number of abnormal cells in the blood, while hydroxyurea is used to reduce the number of white blood cells. The CML drug market is highly competitive, with many companies offering different types of drugs. Some of the major players in the market include Novartis, Bristol-Myers Squibb, Pfizer, and GlaxoSmithKline. Other companies in the market include AbbVie, AstraZeneca, and Merck. Show Less Read more